MNKD MannKind Corporation - Common Stock
MannKind Corporation - Common Stock 정보 위키백과 회사 개요
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
더 보기
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann.
History
Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).
The FDA approved Afrezza on June 27, 2014.
On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.
In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.
Products and product candidates
The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.
Leadership
Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.
In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.
Facilities
MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
MNKD 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
MNKD 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
MNKD 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
- 적극 매수 4 28.6%
- 매수 8 57.1%
- 보유 2 14.3%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
8 명의 애널리스트 · 2026-08-17실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-0.06 | $-0.00 | -0.06% |
| 2026년 3월 31일 | $-0.05 | $-0.00 | -0.05% |
| 2025년 12월 31일 | $-0.05 | $0.01 | -0.06% |
| 2025년 9월 30일 | $0.07 | $0.02 | 0.05% |
| 2025년 6월 30일 | $0.00 | $0.05 | -0.05% |
| 2025년 3월 31일 | $0.04 | $0.04 | -0.00% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | — |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | — |
| AVBP | $854M | -4.7 | — | — | -59.7% | — |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | — |
| CGEM | $624M | -3.2 | — | — | -44.0% | — |
| JBIO | $761M | -4.8 | — | — | -47.7% | — |
| REPL | $633M | -2.3 | — | — | -146.2% | — |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | — |
| AKTS | — | — | — | — | — | — |
| GLUE | $1.03B | — | 63.5% | -31.2% | -15.4% | — |
| CRVS | $575M | -14.5 | — | — | -21.6% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Cost of Revenue | $27M | $17M | $21M | $16M | $17M | $15M | $20M | $19M | $17M | $17M | $65M | · | |
| SG&A Expense | $144M | $94M | $94M | $91M | $32M | $25M | $75M | $80M | $75M | $47M | $41M | $79M | |
| Operating Expenses | $88M | $77M | $63M | $57M | $39M | $25M | $108M | $104M | $120M | $107M | $345M | $180M | |
| Operating Income | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-108M | $67M | $-345M | $-180M | |
| Interest Expense | · | · | $15M | $15M | $15M | · | · | · | · | · | $24M | $20M | |
| Interest Income | $8M | $13M | $6M | $3M | $112.0K | $167.0K | $997.0K | $501.0K | $293.0K | $85.0K | $18.0K | $9.0K | |
| Other Non-op | $-1M | $32.0K | $122.0K | $-102.0K | $-239.0K | $23.0K | $-926.0K | $-437.0K | $13.0K | $-597.0K | $1M | $2M | |
| Pretax Income | $1M | $31M | $-10M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Income Tax | $-4M | $3M | $2M | $0 | $0 | $-218.0K | $0 | $240.0K | $51.0K | $0 | $0 | $0 | |
| Net Income | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| EPS (Basic) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.37 | $-4.54 | $-2.57 | |
| EPS (Diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 | |
| Shares (Basic) | 305,639,000 | 274,415,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,053,000 | 81,233,000 | 77,045,000 | |
| Shares (Diluted) | 314,112,000 | 283,844,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,085,000 | 81,233,000 | 77,045,000 | |
| EBITDA | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-106M | · | $-334M | $-170M |
대차대조표 28
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75M | $46M | $238M | $70M | $124M | $67M | $30M | $71M | $44M | $23M | $59M | $121M | |
| Short-term Investments | $96M | $151M | $57M | $101M | $80M | $0 | $20M | · | · | · | · | · | |
| Receivables | $38M | $12M | $15M | $17M | $5M | $4M | $4M | $4M | $3M | $302.0K | $23.0K | $50M | |
| Inventory | $35M | $28M | $29M | $22M | $7M | $5M | $4M | $4M | $3M | $2M | · | $10M | |
| Prepaid Expense | $47M | $31M | $35M | $25M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $20M | |
| Current Assets | $292M | $268M | $373M | $235M | $219M | $79M | $61M | $82M | $57M | $77M | $77M | $201M | |
| PP&E (Net) | $82M | $85M | $84M | $45M | $37M | $26M | $27M | $26M | $27M | $29M | $49M | $192M | |
| PP&E (Gross) | $196M | $192M | $186M | $144M | $134M | $123M | $122M | $126M | $128M | $129M | $168M | $310M | |
| Accum. Depreciation | $114M | $107M | $102M | $99M | $98M | $97M | $95M | $100M | $101M | $100M | $120M | $118M | |
| Goodwill | $68M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | |
| Intangibles | $5M | $5M | $1M | $1M | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $27M | $7M | $10M | $8M | $3M | $6M | $249.0K | $437.0K | $648.0K | $1M | $848.0K | |
| Total Assets | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Accounts Payable | $9M | $7M | $10M | $11M | $7M | $6M | $5M | $5M | $7M | $3M | $16M | $7M | |
| Accrued Liabilities | $65M | $40M | $42M | $36M | $27M | $20M | $16M | $15M | $12M | $8M | $8M | $26M | |
| Short-term Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Current Liabilities | $171M | $82M | $104M | $67M | $48M | $74M | $66M | $75M | $88M | $92M | $268M | $403M | |
| Capital Leases | $11M | $12M | $4M | $5M | $1M | $1M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $5M | · | · | · | · | · | $15M | $12M | |
| Total Liabilities | $843M | $473M | $721M | $546M | $531M | $289M | $284M | $283M | $299M | $291M | $477M | $468M | |
| Long-term Debt | $355M | $36M | $269M | $273M | $281M | $122M | $119M | $102M | $157M | · | · | · | |
| Total Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $4M | $4M | |
| Retained Earnings | $-3.20B | $-3.20B | $-3.23B | $-3.22B | $-3.13B | $-3.05B | $-2.99B | $-2.94B | $-2.85B | $-2.74B | $-2.86B | $-2.49B | |
| AOCI | $115.0K | $1M | · | · | · | · | $-19.0K | $-19.0K | $-18.0K | $-24.0K | $-20.0K | $-14.0K | |
| Stockholders' Equity | $-51M | $-79M | $-246M | $-251M | $-209M | $-180M | $-191M | $-175M | $-215M | $-184M | $-350M | $-74M | |
| Liabilities + Equity | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Shares Outstanding | 307,832,587 | 302,959,782 | 270,034,495 | 263,793,305 | 251,477,562 | 242,117,089 | 211,787,573 | 187,029,967 | 119,053,414 | 95,680,831 | 85,734,188 | 406,059,089 |
현금 흐름 18
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $7M | $5M | $3M | $2M | $2M | $972.0K | $3M | $2M | $2M | $11M | $10M | |
| Stock-based Comp | $24M | $21M | $18M | $13M | $12M | $7M | $6M | $7M | $5M | $5M | $9M | $49M | |
| Deferred Tax | $-19M | $4M | $7M | $-10M | $-20M | $-5M | $-5M | $-11M | $-260M | $48M | $-80M | $-66M | |
| Amort. of Intangibles | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $6M | $2M | |
| Other Non-cash | · | · | · | · | · | · | · | · | $306M | · | $291M | $144M | |
| Operating Cash Flow | $18M | $43M | $34M | $-81M | $-62M | $-28M | $-88M | $-38M | $-65M | $-78M | $-57M | $4M | |
| CapEx | $5M | $10M | $42M | $8M | $11M | $801.0K | $3M | $354.0K | · | $1M | $10M | $24M | |
| Investing Cash Flow | $-305M | $-97M | $-2M | $5M | $-152M | $15M | $-23M | $-234.0K | $17M | $-1M | · | · | |
| Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | $20M | |
| Net Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $564.0K | $893.0K | $28M | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $564.0K | · | $28M | · | |
| Financing Cash Flow | $315M | $-137M | $137M | $21M | $270M | $50M | $70M | $61M | $74M | $43M | · | · | |
| Net Change in Cash | $29M | $-191M | $169M | $-54M | $57M | $37M | $-41M | $23M | $25M | $-36M | $-62M | $50M | |
| Taxes Paid | $2M | $4M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $14M | $33M | $-8M | $-88M | $-73M | $-29M | $-91M | $-38M | · | · | $-68M | $-20M | |
| Levered FCF | · | · | $-26M | $-98M | · | · | · | · | · | · | $-92M | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -921.1% | · | · | · | |
| Net Margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | · | · | · | |
| Pretax Margin | 0.40% | 10.7% | -5.2% | -87.6% | -107.3% | -88.2% | -82.3% | -311.3% | -998.6% | · | · | · | |
| EBITDA Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -905.8% | · | · | · | |
| ROA | 0.99% | 6.3% | -3.1% | -28.4% | -37.7% | -56.6% | -51.5% | -90.5% | -122.4% | · | -141.5% | -60.8% | |
| ROE | -11.1% | -19.1% | 4.8% | 35.8% | 41.1% | 31.2% | 27.7% | 45.7% | 58.9% | · | 173.8% | 379.7% | |
| ROIC | -316.9% | -83.2% | -4.1% | 25.6% | 22.5% | 26.5% | 24.0% | 43.9% | 50.4% | · | 98.4% | · |
유동성 및 지급능력 4
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 | 1.1 | 0.9 | 1.1 | 0.7 | · | 0.3 | 0.5 | |
| Quick Ratio | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 | 1.0 | 0.8 | 1.0 | 0.5 | · | 0.2 | 0.4 | |
| Debt / Equity | · | · | · | · | · | · | -0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | 0.6 | -6.7 | · | · | · | · | · | · | -14.3 | -8.8 |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.7 | 0.5 | 0.3 | 0.4 | 0.6 | 0.6 | 0.3 | 0.1 | · | 0.0 | · | |
| Inventory Turnover | 0.8 | 0.6 | 0.8 | 1.1 | 2.8 | 3.3 | 5.2 | 6.2 | 6.9 | · | · | · | |
| Receivables Turnover | 13.9 | 21.4 | 12.6 | 9.3 | 16.4 | 16.9 | 16.7 | 8.2 | 7.6 | · | 0.0 | · |
성장률 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 51.8% | 55.8% | 45.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 39.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -80.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -78.8% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 13
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Net Income TTM | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Market Cap | $1.75B | $1.95B | $983M | $1.39B | $1.10B | $758M | $273M | $198M | $276M | · | $3.11B | $10.60B | |
| Enterprise Value | · | · | · | · | · | · | $228M | · | · | · | · | · | |
| P/E | 283.5 | 64.3 | -91.0 | -15.5 | -13.7 | -12.0 | -2.0 | -1.8 | -2.1 | 2.4 | -1.6 | -10.2 | |
| P/S | 5.0 | 6.8 | 4.9 | 13.9 | 14.6 | 11.6 | 4.3 | 7.1 | 23.5 | · | · | · | |
| P/B | -34.2 | -24.7 | -4.0 | -5.5 | -5.2 | -4.2 | -1.4 | -1.1 | -1.3 | · | -8.9 | -143.7 | |
| P / Cash Flow | 95.6 | 45.8 | 28.8 | -17.2 | -17.8 | -26.9 | -3.1 | -5.3 | -4.3 | · | -54.3 | 2593.8 | |
| P / FCF | 127.5 | 59.4 | -117.8 | -15.7 | -15.0 | -26.2 | -3.0 | -5.2 | · | · | -46.0 | -529.6 | |
| EV / EBITDA | · | · | · | · | · | · | -5.1 | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | -2.5 | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | 3.6 | · | · | · | · | · | |
| Earnings Yield | 0.35% | 1.6% | -1.1% | -6.5% | -7.3% | -8.3% | -48.8% | -56.6% | -48.7% | 42.5% | -62.6% | -9.8% |
손익계산서 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109M | $90M | $112M | $82M | $77M | $78M | $77M | $70M | $72M | $66M | $58M | $51M | $49M | $41M | $36M | $33M | |
| Cost of Revenue | $14M | $8M | $14M | $4M | $5M | $4M | $5M | $3M | $6M | $4M | $6M | $4M | $5M | $6M | $4M | $5M | |
| SG&A Expense | $58M | $54M | $58M | $29M | $32M | $25M | $24M | $24M | $24M | $22M | $61M | $11M | $12M | $11M | $64M | $9M | |
| Operating Expenses | $30M | $92M | $-103M | $63M | $21M | $56M | $-86M | $57M | $56M | $50M | $18M | $14M | $14M | $16M | $16M | $17M | |
| Operating Income | $-350.0K | $-2M | $-8M | $19M | $5M | $22M | $26M | $13M | $17M | $17M | $8M | $5M | $2M | $-6M | $-13M | $-10M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $3M | · | $3M | $7M | $3M | · | $3M | |
| Interest Income | $1M | $1M | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $663.0K | |
| Other Non-op | $-5M | $-3M | $23M | $-11M | $-4M | $-9M | $24M | $110.0K | $-18M | $-6M | $-164.0K | $318.0K | $-143.0K | $111.0K | $105.0K | $-207.0K | |
| Pretax Income | $-19M | $-16M | $-21M | $8M | $940.0K | $14M | $8M | $13M | $-2M | $11M | $3M | $2M | $-5M | $-10M | $-18M | $-14M | |
| Income Tax | $-106.0K | $253.0K | $-5M | $-204.0K | $272.0K | $459.0K | $1M | $1M | $323.0K | $264.0K | $2M | $0 | $0 | $0 | · | $0 | |
| Net Income | $-19M | $-17M | $-16M | $8M | $668.0K | $13M | $7M | $12M | $-2M | $11M | $1M | $2M | $-5M | $-10M | $-18M | $-14M | |
| EPS (Basic) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| EPS (Diluted) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| Shares (Basic) | 309,191,000 | 308,267,000 | -609,602,000 | 306,806,000 | 304,954,000 | 303,481,000 | -543,995,000 | 274,998,000 | 273,056,000 | 270,356,000 | -531,313,000 | 268,732,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| Shares (Diluted) | 309,191,000 | 308,267,000 | -629,907,000 | 311,638,000 | 311,484,000 | 320,897,000 | -598,638,000 | 284,693,000 | 273,056,000 | 324,733,000 | -586,351,000 | 323,770,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| EBITDA | · | $-2M | · | $19M | $5M | $22M | · | $13M | $17M | $17M | · | $5M | $2M | $-6M | · | $-10M |
대차대조표 25
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $53M | $75M | $127M | $57M | $47M | $46M | $62M | $97M | $193M | · | $83M | $86M | $86M | · | $54M | |
| Short-term Investments | $58M | $81M | $96M | $133M | $122M | $134M | $151M | $189M | $151M | $107M | · | $58M | $58M | $80M | · | $111M | |
| Receivables | $43M | $28M | $38M | $17M | $27M | $29M | $12M | $18M | $23M | $20M | · | $22M | $28M | $20M | · | $23M | |
| Inventory | $44M | $49M | $35M | $27M | $28M | $29M | $28M | $27M | $25M | $26M | · | $27M | $25M | $22M | · | $18M | |
| Prepaid Expense | $47M | $40M | $47M | $54M | $44M | $34M | $31M | $31M | $30M | $36M | · | $36M | $33M | $15M | · | $12M | |
| Current Assets | $246M | $251M | $292M | $359M | $279M | $274M | $268M | $328M | $326M | $383M | · | $226M | $230M | $223M | · | $218M | |
| PP&E (Net) | $85M | $83M | $82M | $83M | $83M | $84M | $85M | $85M | $85M | $84M | · | $80M | $70M | $55M | · | $41M | |
| PP&E (Gross) | $203M | $198M | $196M | $195M | $194M | $192M | $192M | $192M | $190M | $186M | · | $182M | $170M | $154M | · | $140M | |
| Accum. Depreciation | $118M | $116M | $114M | $113M | $111M | $109M | $107M | $107M | $105M | $103M | · | $101M | $100M | $100M | · | $99M | |
| Goodwill | $68M | $68M | $68M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $3M | |
| Intangibles | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-current Assets | $17M | $22M | $20M | $19M | $20M | $28M | $27M | $26M | $16M | $7M | · | $8M | $8M | $16M | · | $17M | |
| Total Assets | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Accounts Payable | $11M | $16M | $9M | $7M | $10M | $5M | $7M | $6M | $10M | $7M | · | $17M | $17M | $14M | · | $10M | |
| Accrued Liabilities | $61M | $59M | $65M | $31M | $31M | $40M | $40M | $37M | $41M | $42M | · | $32M | $37M | $33M | · | $30M | |
| Current Liabilities | $143M | $135M | $171M | $109M | $112M | $116M | $82M | $72M | $80M | $100M | · | $96M | $97M | $82M | · | $60M | |
| Capital Leases | $10M | $10M | $11M | $10M | $11M | $11M | $12M | $12M | $3M | $4M | · | $4M | $5M | $5M | · | $6M | |
| Total Liabilities | $800M | $804M | $843M | $539M | $467M | $469M | $473M | $674M | $670M | $711M | · | $572M | $574M | $554M | · | $532M | |
| Long-term Debt | $319M | $319M | $355M | $110M | $36M | $36M | $36M | $228M | $228M | $264M | · | $273M | $274M | $274M | · | $273M | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Retained Earnings | $-3.23B | $-3.21B | $-3.20B | $-3.18B | $-3.19B | $-3.19B | $-3.20B | $-3.21B | $-3.22B | $-3.22B | · | $-3.23B | $-3.23B | $-3.23B | · | $-3.20B | |
| AOCI | $-19.0K | $-4.0K | $115.0K | $137.0K | $1M | $1M | $1M | $588.0K | · | · | · | $443.0K | $443.0K | · | · | $-1M | |
| Stockholders' Equity | $-67M | $-59M | $-51M | $-45M | $-55M | $-59M | $-79M | $-210M | $-226M | $-230M | $-246M | $-252M | $-260M | $-255M | $-251M | $-238M | |
| Liabilities + Equity | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Shares Outstanding | 309,911,682 | 308,907,331 | 307,832,587 | 307,027,189 | 306,332,133 | 303,918,969 | 302,959,782 | 275,775,038 | 274,467,247 | 270,801,781 | · | 269,543,539 | 268,235,145 | 264,278,760 | · | 263,156,165 |
현금 흐름 11
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $-427.0K | |
| Stock-based Comp | $10M | $6M | $7M | $4M | $8M | $5M | $6M | $5M | $6M | $4M | $4M | $5M | $6M | $4M | $3M | $4M | |
| Amort. of Intangibles | $4M | $4M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-18M | $-5M | $-8M | $24M | $9M | $-6M | $23M | $9M | $4M | $7M | $22M | $9M | $3M | $1M | $-2M | $-28M | |
| CapEx | $5M | $2M | $2M | $1M | $1M | $330.0K | $3M | $1M | $3M | $2M | $6M | $11M | $17M | $8M | $5M | $271.0K | |
| Investing Cash Flow | $18M | $19M | $-292M | $-25M | $6M | $6M | $48M | $-41M | $-55M | $-48M | $-8M | $-12M | $4M | $14M | $15M | $27M | |
| Financing Cash Flow | $559.0K | $-35M | $247M | $72M | $-6M | $1M | $-87M | $-2M | $-45M | $-3M | $142M | $-283.0K | $-6M | $1M | $3M | $20M | |
| Net Change in Cash | $97.0K | $-22M | $-53M | $70M | $10M | $975.0K | $-16M | $-34M | $-96M | $-45M | $155M | $-3M | $315.0K | $16M | $15M | $19M | |
| Taxes Paid | $753.0K | $63.0K | $549.0K | $80.0K | $869.0K | $207.0K | $2M | $236.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-7M | · | · | · | $-7M | · | · | · | $4M | · | · | · | $-7M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2M | · | · | · | $-10M | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| Net Margin | · | -18.4% | · | 9.7% | 0.87% | 16.8% | · | 16.5% | -2.8% | 16.0% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| Pretax Margin | · | -18.1% | · | 9.5% | 1.2% | 17.4% | · | 18.4% | -2.3% | 16.4% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| EBITDA Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| ROA | · | -2.9% | · | 1.7% | 0.16% | 2.9% | · | 2.9% | -0.53% | 2.7% | · | 0.56% | -1.8% | -3.2% | · | -5.4% | |
| ROE | · | 28.2% | · | -6.3% | -0.48% | -9.1% | · | -5.0% | 0.83% | -4.4% | · | -0.70% | 2.1% | 4.0% | · | 6.8% | |
| ROIC | · | 2.9% | · | -43.5% | -6.8% | -36.8% | · | -5.5% | -8.8% | -7.1% | · | -2.0% | -0.66% | 2.4% | · | · |
유동성 및 지급능력 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 1.9 | · | 3.3 | 2.5 | 2.4 | · | 4.5 | 4.1 | 3.8 | · | 2.3 | 2.4 | 2.7 | · | 3.7 | |
| Quick Ratio | · | 1.2 | · | 2.5 | 1.8 | 1.8 | · | 3.7 | 3.4 | 3.2 | · | 1.7 | 1.8 | 2.3 | · | 3.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 2.7 | 6.5 | · | 1.8 | 0.3 | -2.5 | · | · |
효율성 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.4 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.4 | · | 0.4 | |
| Receivables Turnover | 3.1 | 3.2 | · | 4.6 | 3.0 | 3.2 | · | 3.5 | 2.8 | 3.3 | · | 2.3 | 2.3 | 2.8 | · | 2.0 |
가치 평가 (TTM) 9
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $358M | $327M | · | $307M | $297M | $287M | · | $260M | $239M | $207M | · | $173M | $141M | $104M | · | $86M | |
| Net Income TTM | $-27M | $5M | · | $33M | $23M | $33M | · | $22M | $5M | $-3M | · | $-28M | $-59M | $-79M | · | $-74M | |
| Market Cap | $1.32B | $757M | · | $1.65B | $1.15B | $1.53B | · | $1.73B | $1.43B | $1.23B | · | $1.11B | $1.09B | $1.08B | · | $813M | |
| P/E | -53.2 | 122.5 | · | 48.8 | 53.4 | 45.7 | · | 78.6 | 261.0 | -453.0 | · | -37.5 | -17.7 | -13.2 | · | -10.7 | |
| P/S | 3.7 | 2.3 | · | 5.4 | 3.9 | 5.3 | · | 6.7 | 6.0 | 5.9 | · | 6.4 | 7.7 | 10.4 | · | 9.5 | |
| P/B | -19.6 | -12.8 | · | -37.0 | -20.8 | -26.1 | · | -8.3 | -6.3 | -5.3 | · | -4.4 | -4.2 | -4.2 | · | -3.4 | |
| P / Cash Flow | · | -141.1 | · | · | · | -239.7 | · | · | · | 183.0 | · | · | · | 937.3 | · | · | |
| P / FCF | · | -104.5 | · | · | · | -227.9 | · | · | · | 285.6 | · | · | · | -151.4 | · | · | |
| Earnings Yield | -1.9% | 0.82% | · | 2.1% | 1.9% | 2.2% | · | 1.3% | 0.38% | -0.22% | · | -2.7% | -5.7% | -7.6% | · | -9.4% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $349M | $286M | $199M | $100M | $75M |
| 영업이익률 % | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| 순이익 | $6M | $28M | $-12M | $-87M | $-81M |
| 희석 EPS | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 |
| 당좌 비율 | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $14M | $33M | $-8M | $-88M | $-73M |
최신 뉴스 이 회사 관련 최근 헤드라인
트레이딩 시그널 진입 가격 및 위험/보상 비율을 포함한 최근 매수/매도 신호
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 273개의 제출자 · $560.8M 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 49 (-2 이전 분기 대비) | 38 (-9 이전 분기 대비) | 96 (+12 이전 분기 대비) | 62 (-7 이전 분기 대비) | +5.4M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| Rubric Capital Management LP | $76,680,000 | 18,000,000 | 13.67% | 주식 |
| STATE STREET CORP | $68,901,423 | 16,174,043 | 12.29% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $56,101,610 | 13,169,392 | 10.00% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $29,027,881 | 6,812,460 | 5.18% | 주식 |
| Frazier Life Sciences Management, L.P. | $28,116,000 | 6,600,000 | 5.01% | 주식 |
| Deep Track Capital, LP | $25,560,000 | 6,000,000 | 4.56% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $23,099,232 | 5,422,355 | 4.12% | 주식 |
| 180 WEALTH ADVISORS, LLC | $21,126,835 | 4,959,351 | 3.77% | 주식 |
| FMR LLC | $17,455,563 | 4,097,550 | 3.11% | 주식 |
| TSP Capital Management Group, LLC | $16,923,596 | 3,972,675 | 3.02% | 주식 |
| BRAIDWELL LP | $14,732,908 | 3,458,429 | 2.63% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12,789,240 | 3,002,169 | 2.28% | 주식 |
| VANGUARD GROUP INC | $11,888,249 | 2,096,693 | 2.12% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $11,475,213 | 2,693,712 | 2.05% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11,070,577 | 2,598,727 | 1.97% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $9,358,279 | 2,196,779 | 1.67% | 주식 |
| BANK OF AMERICA CORP /DE/ | $8,689,749 | 2,039,847 | 1.55% | 주식 |
| GOLDMAN SACHS GROUP INC | $6,332,618 | 1,486,530 | 1.13% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5,030,221 | 1,180,803 | 0.90% | 주식 |
| BlackRock, Inc. | $4,766,748 | 1,118,955 | 0.85% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $4,486,321 | 1,053,127 | 0.80% | 주식 |
| Caption Management, LLC | $4,260,000 | 1,000,000 | 0.76% | 풋 옵션 |
| J. Goldman & Co LP | $3,478,669 | 816,589 | 0.62% | 주식 |
| WELLS FARGO & COMPANY/MN | $3,473,987 | 815,490 | 0.62% | 주식 |
| SCOPIA CAPITAL MANAGEMENT LP | $2,960,534 | 694,961 | 0.53% | 주식 |
| Balyasny Asset Management L.P. | $2,914,296 | 684,107 | 0.52% | 주식 |
| TWO SIGMA ADVISERS, LP | $2,897,166 | 510,964 | 0.52% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $2,771,407 | 650,565 | 0.49% | 주식 |
| Swiss National Bank | $2,502,324 | 587,400 | 0.45% | 주식 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,177,052 | 511,045 | 0.39% | 주식 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2,106,540 | 494,493 | 0.38% | 주식 |
| 1492 Capital Management LLC | $2,052,136 | 481,722 | 0.37% | 주식 |
| Mariner, LLC | $2,020,189 | 474,236 | 0.36% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $1,836,597 | 431,126 | 0.33% | 주식 |
| Schonfeld Strategic Advisors LLC | $1,774,216 | 416,483 | 0.32% | 주식 |
| Squarepoint Ops LLC | $1,759,644 | 413,062 | 0.31% | 주식 |
| Jefferies Financial Group Inc. | $1,694,202 | 397,700 | 0.30% | 주식 |
| ExodusPoint Capital Management, LP | $1,666,261 | 391,141 | 0.30% | 주식 |
| JANE STREET GROUP, LLC | $1,658,418 | 389,300 | 0.30% | 콜 옵션 |
| Man Group plc | $1,624,023 | 381,226 | 0.29% | 주식 |
| RHUMBLINE ADVISERS | $1,604,647 | 376,681 | 0.29% | 주식 |
| IEQ CAPITAL, LLC | $1,544,607 | 362,584 | 0.28% | 주식 |
| CITIGROUP INC | $1,499,243 | 351,935 | 0.27% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,423,692 | 334,200 | 0.25% | 풋 옵션 |
| Bank of New York Mellon Corp | $1,422,222 | 333,855 | 0.25% | 주식 |
| Caption Management, LLC | $1,414,231 | 331,979 | 0.25% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $1,359,221 | 319,066 | 0.24% | 주식 |
| ALPS ADVISORS INC | $1,330,615 | 312,351 | 0.24% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,216,230 | 285,500 | 0.22% | 콜 옵션 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1,029,075 | 241,567 | 0.18% | 주식 |
| BARCLAYS PLC | $1,029,062 | 241,564 | 0.18% | 주식 |
| Rafferty Asset Management, LLC | $1,008,640 | 236,770 | 0.18% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $1,002,715 | 235,379 | 0.18% | 주식 |
| Aaron Wealth Advisors LLC | $1,000,878 | 234,948 | 0.18% | 주식 |
| HSBC HOLDINGS PLC | $998,560 | 230,881 | 0.18% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $930,294 | 379,712 | 0.17% | 주식 |
| CITADEL ADVISORS LLC | $928,680 | 218,000 | 0.17% | 콜 옵션 |
| CITADEL ADVISORS LLC | $898,860 | 211,000 | 0.16% | 풋 옵션 |
| Bruce & Co., Inc. | $831,011 | 195,073 | 0.15% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $775,060 | 181,939 | 0.14% | 주식 |
| MetLife Investment Management, LLC | $766,442 | 179,916 | 0.14% | 주식 |
| FRANKLIN RESOURCES INC | $755,021 | 177,235 | 0.13% | 주식 |
| Stonepine Capital Management, LLC | $750,000 | 250,000 | 0.13% | 콜 옵션 |
| UBS Group AG | $715,978 | 168,070 | 0.13% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $693,375 | 283,010 | 0.12% | 주식 |
| MORGAN STANLEY | $651,282 | 152,883 | 0.12% | 주식 |
| TUDOR INVESTMENT CORP ET AL | $640,657 | 150,389 | 0.11% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $632,009 | 148,359 | 0.11% | 주식 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $613,437 | 171,372 | 0.11% | 주식 |
| Jain Global LLC | $604,673 | 141,942 | 0.11% | 주식 |
| KING LUTHER CAPITAL MANAGEMENT CORP | $590,457 | 138,605 | 0.11% | 주식 |
| Susquehanna Portfolio Strategies, LLC | $574,538 | 134,868 | 0.10% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $570,354 | 133,886 | 0.10% | 주식 |
| MERCER GLOBAL ADVISORS INC /ADV | $557,723 | 130,921 | 0.10% | 주식 |
| PROFUND ADVISORS LLC | $517,726 | 121,532 | 0.09% | 주식 |
| Invesco Ltd. | $512,389 | 120,279 | 0.09% | 주식 |
| Vanguard Global Advisers, LLC | $509,833 | 119,679 | 0.09% | 주식 |
| KLP KAPITALFORVALTNING AS | $491,604 | 115,400 | 0.09% | 주식 |
| Gotham Asset Management, LLC | $452,463 | 106,212 | 0.08% | 주식 |
| State of New Jersey Common Pension Fund D | $403,171 | 94,641 | 0.07% | 주식 |
| State of Wyoming | $403,149 | 94,636 | 0.07% | 주식 |
| Police & Firemen's Retirement System of New Jersey | $386,834 | 90,806 | 0.07% | 주식 |
| Amundi | $374,310 | 87,866 | 0.07% | 주식 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $373,478 | 87,671 | 0.07% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $359,966 | 84,499 | 0.06% | 주식 |
| ARIZONA STATE RETIREMENT SYSTEM | $344,050 | 80,763 | 0.06% | 주식 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $338,155 | 79,379 | 0.06% | 주식 |
| Aquatic Capital Management LLC | $335,300 | 78,709 | 0.06% | 주식 |
| Rockefeller Capital Management L.P. | $332,996 | 78,168 | 0.06% | 주식 |
| Vanguard Investments Australia, Ltd. | $314,929 | 73,927 | 0.06% | 주식 |
| JANUS HENDERSON GROUP PLC | $313,658 | 127,763 | 0.06% | 주식 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $312,203 | 73,287 | 0.06% | 주식 |
| Sequoia Financial Advisors, LLC | $296,935 | 69,703 | 0.05% | 주식 |
| INTECH INVESTMENT MANAGEMENT LLC | $284,653 | 66,820 | 0.05% | 주식 |
| COMMONWEALTH EQUITY SERVICES, LLC | $280,421 | 65,827 | 0.05% | 주식 |
| China Universal Asset Management Co., Ltd. | $262,714 | 61,670 | 0.05% | 주식 |
| LPL Financial LLC | $260,060 | 61,047 | 0.05% | 주식 |
| SIMPLEX TRADING, LLC | $258,790 | 60,749 | 0.05% | 주식 |
| Cetera Investment Advisers | $241,546 | 56,701 | 0.04% | 주식 |
| Painted Porch Advisors LLC | $227,620 | 53,432 | 0.04% | 주식 |
회사 내부자 43 명의 내부자 · 27 임원 · 18 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer | 2026년 7월 15일 M | 2,433,779 | 1 | 4 | $-990,292 |
| Hakan Edstrom | President & CEO | 2015년 8월 27일 A | 1,114,340 | 0 | 0 | $0 |
| Christopher B Prentiss | Chief Financial Officer | 2026년 7월 15일 F | 318,668 | 0 | 0 | $0 |
| Juergen Martens | Corporate VP and COO | 2015년 8월 27일 A | 106,539 | 0 | 0 | $0 |
| Dominic Marasco | Pres, Endocrine Business Unit | 2026년 7월 15일 F | 343,398 | 0 | 0 | $0 |
| Sanjay R Singh | EVP Technical Operations | 2026년 7월 15일 M | 478,966 | 0 | 1 | $-94,448 |
| Stuart A Tross | Chief People & Workpl Officer | 2026년 7월 15일 M | 1,058,142 | 0 | 2 | $-548,528 |
| David Thomson | EVP Genl Counsel & Secretary | 2026년 7월 15일 M | 797,554 | 0 | 3 | $-930,755 |
| Ajay Ahuja | Chief Medical Officer | 2026년 3월 23일 A | 318,200 | 0 | 0 | $0 |
| Lauren M Sabella | EVP Operations | 2025년 7월 15일 F | 349,841 | 0 | 0 | $0 |
| Burkhard Blank | EVP Chief Medical Officer | 2025년 7월 15일 F | 460,791 | 0 | 0 | $0 |
| Joseph Kocinsky | Chief Technology Officer | 2022년 8월 27일 F | 745,233 | 0 | 0 | $0 |
| Alejandro Galindo | EVP Endocrine Business Unit | 2022년 2월 28일 A | 576,690 | 0 | 0 | $0 |
| Rosabel Realica Alinaya | VP, IR & Treasury | 2020년 8월 27일 A | 167,119 | 0 | 0 | $0 |
| David M Kendall | Chief Medical Officer | 2020년 7월 31일 P | 41,059 | 0 | 0 | $0 |
| Patrick Mccauley | Chief Commercial Officer | 2020년 2월 25일 A | 83,972 | 0 | 0 | $0 |
| Courtney Barton | Chief Compl & Privacy Officer | 2019년 7월 31일 P | 29,584 | 0 | 0 | $0 |
| Elizabeth Garrett Ingram | Chief Marketing Officer | 2019년 5월 14일 A | 43,012 | 0 | 0 | $0 |
| Raymond W. Urbanski | Corp VP, CMO | 2017년 8월 10일 S | 2,924 | 0 | 0 | $0 |
| Linda A Adreveno | Sr. VP, HR | 2016년 2월 18일 A | 92,200 | 0 | 0 | $0 |
| Alfred E Mann | Executive Chairman | 2015년 8월 22일 F | 1,005,990 | 0 | 0 | $0 |
| Diane Palumbo | Vice President, Human Resource | 2015년 2월 23일 F | 50,624 | 0 | 0 | $0 |
| Peter C Richardson | Chief Scientific Officer | 2012년 3월 3일 F | 133,611 | 0 | 0 | $0 |
| Richard L Anderson | Corporate VP | 2008년 11월 16일 F | 204,401 | 0 | 0 | $0 |
| John R. Riesenberger | VP & Chief Commercial Officer | 2008년 8월 13일 A | 14,650 | 0 | 0 | $0 |
| Dan Burns | VP & President, MKBP | 2006년 12월 8일 A | 14,800 | 0 | 0 | $0 |
| Wendell W Cheatham | VP, Medical & Reg Affairs | 2004년 8월 19일 A | 300 | 0 | 0 | $0 |
| Sabrina Kay | 이사 | 2026년 5월 20일 A | 265,600 | 0 | 0 | $0 |
| Jennifer Grancio | 이사 | 2026년 5월 20일 A | 244,815 | 0 | 0 | $0 |
| James Samuel Shannon | 이사 | 2026년 5월 20일 A | 64,635 | 0 | 0 | $0 |
| Michael A Friedman | 이사 | 2026년 5월 20일 A | 47,500 | 0 | 0 | $0 |
| Anthony C Hooper | 이사 | 2026년 5월 20일 A | 236,153 | 0 | 0 | $0 |
| Christine Mundkur | 이사 | 2026년 5월 20일 A | 254,493 | 0 | 0 | $0 |
| Ronald J Consiglio | 이사 | 2026년 5월 20일 A | 132,342 | 0 | 0 | $0 |
| Kent Kresa | 이사 | 2024년 5월 15일 A | 274,541 | 0 | 0 | $0 |
| Henry L Nordhoff | 이사 | 2019년 5월 14일 A | 103,426 | 0 | 0 | $0 |
| David Maccallum | 이사 | 2018년 5월 16일 A | 114,790 | 0 | 0 | $0 |
| Matthew J Pfeffer | 이사 | 2017년 8월 28일 F | 81,961 | 0 | 0 | $0 |
| Abraham E Cohen | 이사 | 2012년 8월 17일 S | 56,424 | 0 | 0 | $0 |
| Heather Hay Murren | 이사 | 2008년 8월 13일 A | 10,100 | 0 | 0 | $0 |
| Kathleen Connell | 이사 | 2006년 5월 25일 A | — | 0 | 0 | $0 |
| Llew Keltner | 이사 | 2006년 5월 25일 A | — | 0 | 0 | $0 |
| Steven B. Binder | — | 2026년 8월 7일 S | 785,867 | 0 | 3 | $-427,369 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 2 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 제출 서류 | 2012년 7월 10일 | — | 최초 제출 | 수동적 투자 | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2006년 1월 31일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 42 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| RNIN · EA Series Trust | 1.43% | 773,251 NS | 2026년 4월 30일 | N-PORT |
| SBIO · ALPS ETF Trust | 0.74% | 317,578 NS | 2026년 5월 31일 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.53% | 29,662 SH | 2026년 8월 19일 | 일간 |
| AGNG · Global X Funds | 0.46% | 98,947 NS | 2026년 5월 31일 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.34% | 625,921 NS | 2026년 4월 30일 | N-PORT |
| GINN · Goldman Sachs ETF Trust | 0.11% | 64,525 NS | 2026년 5월 31일 | N-PORT |
| IBB · iShares Trust | 0.09% | 2,194,293 SH | 2026년 8월 19일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.08% | 17,098 SH | 2026년 8월 19일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.08% | 330,117 SH | 2026년 8월 19일 | 일간 |
| IWO · iShares Trust | 0.08% | 2,783,818 SH | 2026년 8월 19일 | 일간 |
| PSC · Principal Exchange-Traded Funds | 0.07% | 354,917 NS | 2026년 6월 30일 | N-PORT |
| ESML · iShares Trust | 0.06% | 447,380 SH | 2026년 8월 19일 | 일간 |
| BIB · ProShares Trust | 0.06% | 11,389 NS | 2026년 5월 31일 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.04% | 114,273 NS | 2026년 4월 30일 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.04% | 1,771,496 SH | 2026년 8월 19일 | 일간 |
| IWM · iShares Trust | 0.04% | 7,900,932 SH | 2026년 8월 19일 | 일간 |
| ISCG · iShares Trust | 0.04% | 94,032 SH | 2026년 8월 19일 | 일간 |
| ITWO · ProShares Trust | 0.03% | 14,400 NS | 2026년 5월 31일 | N-PORT |
| RSSL · Global X Funds | 0.03% | 132,607 NS | 2026년 4월 30일 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.02% | 1,466,402 NS | 2026년 5월 31일 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.02% | 61,465 NS | 2026년 5월 31일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.02% | 874,372 SH | 2026년 8월 19일 | 일간 |
| ISCB · iShares Trust | 0.02% | 13,557 SH | 2026년 8월 19일 | 일간 |
| UWM · ProShares Trust | 0.02% | 11,261 NS | 2026년 5월 31일 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 135,688 NS | 2026년 4월 30일 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.01% | 638,128 NS | 2026년 4월 30일 | N-PORT |
| URTY · ProShares Trust | 0.01% | 11,390 NS | 2026년 5월 31일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 3,543,398 SH | 2026년 8월 19일 | 일간 |
| WSML · iShares Trust | 0.01% | 16,464 SH | 2026년 8월 19일 | 일간 |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.01% | 12,000 NS | 2026년 5월 31일 | N-PORT |
| HDG · ProShares Trust | 0.01% | 286 NS | 2026년 5월 31일 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 452,118 NS | 2026년 4월 30일 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 27,701 NS | 2026년 4월 30일 | N-PORT |
| ITOT · iShares Trust | 0.00% | 466,285 SH | 2026년 8월 19일 | 일간 |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.00% | 1,330 NS | 2026년 5월 31일 | N-PORT |
| IWV · iShares Trust | 0.00% | 83,490 SH | 2026년 8월 19일 | 일간 |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 196,006 NS | 2026년 5월 31일 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 10,345 NS | 2026년 4월 30일 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 32,093 NS | 2026년 4월 30일 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 14,557 NS | 2026년 4월 30일 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 9,327,332 SH | 2026년 8월 19일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 26,184 SH | 2026년 8월 19일 | 일간 |